西妥昔单抗联合放疗对比顺铂联合放疗治疗局部晚期头颈癌:随机II期试验长期生存与毒性结果
多中心随机II期试验入组70例局部晚期头颈癌患者,比较放疗联合每周顺铂或西妥昔单抗的长期生存与晚期毒性。两组晚期毒性无显著差异,5年局部控制率、无转移生存率、总生存率和癌症特异性生存率差异均未达统计学显著。
要点
- 两组晚期毒性(口干、纤维化、黏膜萎缩、体重下降)无统计学显著差异。
- 顺铂组与西妥昔单抗组5年局部控制率分别为67%和48%,差异未达统计学显著。
- HPV阳性口咽癌亚组顺铂组生存更优,但样本量小未行统计学检验。
核心结论
- 长期结果与现有文献一致,提示西妥昔单抗联合放疗在局部晚期头颈癌根治性治疗中劣于顺铂联合放疗。
- 西妥昔单抗虽不能替代顺铂,但可能在局部晚期头颈癌中仍有一定作用,尤其是HPV阴性病例。
研究设计与样本
- 多中心随机II期试验,2011年1月至2014年8月入组70例局部晚期头颈癌患者。
- 患者随机接受放疗联合每周顺铂(40 mg/m2)或西妥昔单抗(负荷剂量400 mg/m2后250 mg/m2)。
- 更新分析聚焦晚期毒性(CTCAE 4.0分级)及局部控制、总生存、癌症特异性生存和无转移生存的长期结局,并补充HPV状态分析。
主要发现
- 晚期毒性(口干、纤维化、黏膜萎缩、体重下降)两组间无统计学显著差异。
- 顺铂组与西妥昔单抗组5年局部控制率分别为67%和48%,差异未达统计学显著。
- 顺铂组与西妥昔单抗组5年无转移生存率分别为83%和97%,差异未达统计学显著。
- 顺铂组与西妥昔单抗组5年总生存率分别为61%和52%,差异未达统计学显著。
- 顺铂组与西妥昔单抗组5年癌症特异性生存率分别为70%和59%,差异未达统计学显著。
关键数值与推荐
- HPV阳性口咽癌亚组中顺铂组生存更优,但因样本量小未行统计学检验。
- HPV阴性口咽癌及其他解剖亚部位中,除西妥昔单抗组无转移生存率确认更优外,未见统计学显著差异。
临床怎么用
- 对于局部晚期头颈癌根治性治疗,顺铂联合放疗仍为优先选择,西妥昔单抗联合放疗不作为顺铂的替代方案。
- 在HPV阴性病例中,西妥昔单抗联合放疗可能仍有一定作用,需结合患者具体情况个体化考虑。
局限性
- 为II期随机试验,样本量较小(70例),统计效能有限。
- HPV阳性口咽癌亚组因样本量小未行统计学检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study describes the long-term survival and toxicity outcomes of a multicenter randomized phase 2 trial comparing radiation therapy (RT) plus cisplatin (CDDP) or cetuximab (CTX) as first line treatment in locally advanced head and neck cancer (LASCCHN). METHODS AND MATERIALS: Between January 2011 and August 2014, 70 patients were enrolled and randomized to receive RT plus weekly CDDP (40 mg/m2) or CTX (250 mg/m2 plus a loading dose of 400 mg/m2). This updated series focuses on late toxicities (graded by using Common Terminology Criteria for Adverse Events version 4.0) and long-term survival outcomes in terms of local control, overall survival, cancer-specific survival, and metastasis-free survival (MFS). A supplementary analysis based on human papilloma virus (HPV) status was also performed. RESULTS: No statistically significant difference was found in terms of late effects (xerostomia, fibrosis, mucosal atrophy, weight loss). In the CDDP arm and the CTX arm, 5-year local control rates were 67% and 48%; 5-year MFS rates were 83% and 97%; 5-year overall survival rates were 61% and 52%; and 5-year cancer-specific survival rates were 70% and 59%, respectively. None of these differences reached statistical significance. A subgroup analysis by HPV status and anatomic subsites revealed that in HPV+ oropharyngeal carcinoma, better survival was obtained in the CDDP arm (although statistical tests were not performed owing to the small sample size). Conversely, no statistically significant differences were observed in HPV- oropharyngeal carcinoma and other anatomic subsites, except for the confirmed better MFS rates of the CTX arm. CONCLUSIONS: Long-term results are in line with current literature suggesting that RT + CTX is inferior to RT + CDDP for the definitive treatment of LASCCHN. However, if not as an alternative to CDDP, CTX might still play a role in LASCCHN, particularly in HPV- cases.
引用
- Maddalo M, Borghetti P, Tomasini D, et al. Cetuximab and Radiation Therapy Versus Cisplatin and Radiation Therapy for Locally Advanced Head and Neck Cancer: Long-Term Survival and Toxicity Outcomes of a Randomized Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2020. PMID: 32184121. doi:10.1016/j.ijrobp.2020.02.637
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。